Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema

Trial Profile

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 17 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 12 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top